Guardant Health Inc. Common Stock vs Liquidia Corporation Common Stock — how do they compare? Guardant Health Inc. Common Stock trades at $163.01 (market cap $21.74B), while Liquidia Corporation Common Stock trades at $33.46 (market cap $2.40B). The key difference: Guardant Health Inc. Common Stock is far larger — about 9.1× Liquidia Corporation Common Stock's market cap, and Guardant Health Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 3 Days and Liquidia Corporation Common Stock for 0 Days on average.
| GH | LQDA | |
|---|---|---|
Market Cap | $21.74B | $2.40B |
Volume | 1,297,295 | 2,857,547 |
Sector | Health | Health |
52-Week High | $187.22 | $91.03 |
52-Week Low | $64.19 | $22.02 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $22.38B | $2.30B |
Signals from Pluang's Aura AI — not financial advice
Guardant Health (GH) trades at $162.09, down 0.43% today, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth to $982M in 2025 but remains unprofitable with a -38.33% net margin. Recent FDA and European approvals for cancer diagnostics and expanded insurance coverage provide significant growth catalysts.
Investment outlook balances high growth potential against persistent losses. Analyst consensus is strongly bullish with a $202.40 price target (25% upside), but investors face execution risk as the company burns cash and misses earnings estimates. The stock offers substantial upside if Guardant can achieve profitability through its expanding product portfolio.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →